Lisata Therapeutics (NASDAQ:LSTA) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Lisata Therapeutics (NASDAQ:LSTA) to a hold rating in a research report report published on Monday morning,Zacks.com reports.

A number of other brokerages have also issued reports on LSTA. lowered shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright lowered shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $15.00.

Lisata Therapeutics Stock Performance

Shares of LSTA opened at $3.12 on Monday. The firm has a market cap of $28.42 million, a PE ratio of -1.68 and a beta of 0.81. The company’s 50 day simple moving average is $4.19 and its 200-day simple moving average is $3.37. Lisata Therapeutics has a 12-month low of $1.81 and a 12-month high of $5.07.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter. As a group, equities research analysts forecast that Lisata Therapeutics will post -1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

Institutional investors have recently made changes to their positions in the stock. Cerity Partners LLC purchased a new stake in shares of Lisata Therapeutics during the 2nd quarter worth $32,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Lisata Therapeutics during the 3rd quarter worth $37,000. SOL Capital Management CO purchased a new stake in shares of Lisata Therapeutics during the 1st quarter worth $61,000. Ground Swell Capital LLC purchased a new stake in shares of Lisata Therapeutics during the 3rd quarter worth $62,000. Finally, Renaissance Technologies LLC boosted its position in shares of Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after purchasing an additional 7,093 shares in the last quarter. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.